Overview

Glucagon Use in Colonoscopies

Status:
Completed
Trial end date:
2018-05-01
Target enrollment:
0
Participant gender:
All
Summary
The investigators believe that glucagon therapy will have a positive impact on key parameters of colonoscopy such as cecal intubation time, withdrawal time, total procedure time, adenoma detection rate, endoscopist's assessment of the difficulty of the procedure, patient comfort, and patient's willingness to undergo a repeat colonoscopy.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of California, San Francisco
Treatments:
Glucagon
Glucagon-Like Peptide 1
Criteria
Inclusion Criteria:

- Any subject who has already been already cleared for and scheduled to undergo
colonoscopy at SFGH endoscopy center.

Exclusion Criteria:

1. Refusal to give informed consent.

2. Age <18 or >70.

3. Prior intra-abdominal surgery

4. Diabetes

5. Pheochromocytoma

6. Insulinoma

7. Liver disease (Child-Pugh Score >6)

8. Pregnancy